NO20006336D0 - Glukagon-liknende peptid-1 forbedrer <beta>-celle respons på glukose i individer med svekket glukosetoleranse - Google Patents

Glukagon-liknende peptid-1 forbedrer <beta>-celle respons på glukose i individer med svekket glukosetoleranse

Info

Publication number: NO20006336D0
Authority: NO; Norway
Prior art keywords: glucagon; individuals; enhances; peptide; beta
Prior art date: 1998-06-12

Application number

NO20006336A

Other languages

English (en)

Other versions

NO20006336L (no

Inventor

Burhard Goke

Maria Byrne

Original Assignee

Bionebraska Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-12

Filing date

2000-12-12

Publication date

2000-12-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22215287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006336(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-12 Application filed by Bionebraska Inc filed Critical Bionebraska Inc

2000-12-12 Publication of NO20006336D0 publication Critical patent/NO20006336D0/no

2001-02-12 Publication of NO20006336L publication Critical patent/NO20006336L/no

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
101800000224 Glucagon-like peptide 1 Proteins 0.000 title 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
208000002705 Glucose Intolerance Diseases 0.000 title 1
102100040918 Pro-glucagon Human genes 0.000 title 1
230000036755 cellular response Effects 0.000 title 1
239000008103 glucose Substances 0.000 title 1
201000009104 prediabetes syndrome Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Zoology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20006336A 1998-06-12 2000-12-12 Glukagon-liknende peptid-1 forbedrer <beta>-celle respons på glukose i individer med svekket glukosetoleranse NO20006336L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8904498P	1998-06-12	1998-06-12
PCT/US1999/010040 WO1999064061A1 (en)	1998-06-12	1999-05-07	GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE

Publications (2)

Publication Number	Publication Date
NO20006336D0 true NO20006336D0 (no)	2000-12-12
NO20006336L NO20006336L (no)	2001-02-12

Family

ID=22215287

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20006336A NO20006336L (no)	1998-06-12	2000-12-12	Glukagon-liknende peptid-1 forbedrer <beta>-celle respons på glukose i individer med svekket glukosetoleranse

Country Status (30)

Country	Link
US (1)	US7265087B1 (no)
EP (2)	EP1083924B1 (no)
JP (1)	JP2002517469A (no)
KR (1)	KR20010052800A (no)
CN (1)	CN1209166C (no)
AP (1)	AP2001002027A0 (no)
AT (1)	ATE270897T1 (no)
AU (2)	AU758825B2 (no)
BG (1)	BG64975B1 (no)
BR (1)	BR9911112A (no)
CA (1)	CA2334872C (no)
CZ (1)	CZ294848B6 (no)
DE (1)	DE69918691T2 (no)
DK (1)	DK1083924T3 (no)
EA (1)	EA004538B1 (no)
ES (1)	ES2224659T3 (no)
GE (1)	GEP20033015B (no)
HU (1)	HUP0102193A2 (no)
ID (1)	ID28617A (no)
IL (2)	IL140223A0 (no)
MX (1)	MXPA00012286A (no)
NO (1)	NO20006336L (no)
NZ (2)	NZ508823A (no)
OA (1)	OA11694A (no)
PL (1)	PL195662B1 (no)
PT (1)	PT1083924E (no)
SK (1)	SK19042000A3 (no)
TR (1)	TR200100079T2 (no)
UA (1)	UA69412C2 (no)
WO (1)	WO1999064061A1 (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US20020025306A1 (en) *	2000-01-07	2002-02-28	Baetge Edward E.	Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1274720A4 (en)	2000-04-12	2004-08-18	Human Genome Sciences Inc	FUSION PROTEINS CONTAINING ALBUMIN
EP1346722B1 (en)	2000-12-01	2008-12-10	Takeda Pharmaceutical Company Limited	Method for producing preparation containing bioactive substance
PT1463751E (pt)	2001-12-21	2013-08-26	Human Genome Sciences Inc	Proteínas de fusão de albumina
EP1494732B1 (en)	2002-03-20	2008-01-30	MannKind Corporation	Inhalation apparatus
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
US8921311B2 (en) *	2003-08-01	2014-12-30	Mannkind Corporation	Method for treating hyperglycemia
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
CA2606902A1 (en) *	2005-05-27	2006-11-30	Asubio Pharma Co., Ltd.	Insulin resistance improver
AU2006290227B2 (en)	2005-09-14	2012-08-02	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
AU2007240313B2 (en)	2006-04-20	2012-02-02	Amgen Inc.	GLP-1 compounds
KR101106510B1 (ko)	2006-05-30	2012-01-20	인타르시아 세라퓨틱스 인코포레이티드	투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2670821C (en)	2006-08-09	2012-05-15	Intarcia Therapeutics, Inc.	Osmotic delivery systems and piston assemblies
RU2413528C2 (ru)	2007-01-18	2011-03-10	Открытое Акционерное Общество "Валента Фармацевтика"	Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
CA2683610C (en)	2007-04-23	2013-01-08	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
AU2008297885A1 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of GLP-1 as a therapeutic agent
RU2010114049A (ru) *	2007-09-11	2011-10-20	Мондобайотек Лабораториз Аг (Li)	Cgrp в качестве терапевтического средства
WO2009102467A2 (en)	2008-02-13	2009-08-20	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
SG10201507036TA (en)	2008-06-13	2015-10-29	Mannkind Corp	A dry powder inhaler and system for drug delivery
EP2609954B1 (en)	2008-06-20	2021-12-29	MannKind Corporation	An interactive apparatus for real-time profiling of inhalation efforts
US20120058105A1 (en) *	2008-06-27	2012-03-08	Martin Kean Chong Ng	Method of treatment of vascular complications
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
MX378797B (es)	2009-09-28	2025-03-10	Intarcia Therapeutics Inc	Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2694402B1 (en)	2011-04-01	2017-03-22	MannKind Corporation	Blister package for pharmaceutical cartridges
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
HK1200318A1 (en)	2011-10-24	2015-08-07	曼金德公司	Methods and compositions for treating pain
JP6224586B2 (ja)	2012-07-10	2017-11-01	武田薬品工業株式会社	注射用製剤
EP2872205B1 (en)	2012-07-12	2017-02-08	MannKind Corporation	Dry powder drug delivery systems
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru)	2014-08-21	2016-01-27	Дафот Энтерпрайсис Лимитед	Пептид для лечения сахарного диабета 2-го типа и его осложнений
CN104267194B (zh) *	2014-09-23	2016-01-13	上海市东方医院	人胰高血糖素样肽-1、抗体及其试剂盒
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
CN113598842A (zh)	2015-06-03	2021-11-05	因塔西亚制药公司	植入物放置和移除系统
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
WO2018129058A1 (en)	2017-01-03	2018-07-12	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
WO2020103729A1 (zh) *	2018-11-12	2020-05-28	天津药物研究院有限公司	胰高血糖素衍生肽及其用途
CN113430154A (zh) *	2021-05-21	2021-09-24	深圳市前海金卓生物技术有限公司	分泌glp-1的蛋白表达系统及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU723694B2 (en)	1996-06-05	2000-08-31	Roche Diagnostics Gmbh	Exendin analogues, processes for their preparation and medicaments containing them
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6344180B1 (en) *	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes

1999
- 1999-05-07 NZ NZ508823A patent/NZ508823A/en not_active IP Right Cessation
- 1999-05-07 EP EP99921778A patent/EP1083924B1/en not_active Revoked
- 1999-05-07 MX MXPA00012286A patent/MXPA00012286A/es unknown
- 1999-05-07 ES ES99921778T patent/ES2224659T3/es not_active Expired - Lifetime
- 1999-05-07 EP EP04075402A patent/EP1419783A3/en not_active Withdrawn
- 1999-05-07 DE DE69918691T patent/DE69918691T2/de not_active Revoked
- 1999-05-07 JP JP2000553129A patent/JP2002517469A/ja active Pending
- 1999-05-07 EA EA200100029A patent/EA004538B1/ru not_active IP Right Cessation
- 1999-05-07 AT AT99921778T patent/ATE270897T1/de not_active IP Right Cessation
- 1999-05-07 WO PCT/US1999/010040 patent/WO1999064061A1/en not_active Ceased
- 1999-05-07 ID IDW20010100A patent/ID28617A/id unknown
- 1999-05-07 NZ NZ527473A patent/NZ527473A/en not_active IP Right Cessation
- 1999-05-07 BR BR9911112-8A patent/BR9911112A/pt not_active IP Right Cessation
- 1999-05-07 US US09/719,410 patent/US7265087B1/en not_active Expired - Fee Related
- 1999-05-07 CN CNB998091812A patent/CN1209166C/zh not_active Expired - Fee Related
- 1999-05-07 AP APAP/P/2001/002027A patent/AP2001002027A0/en unknown
- 1999-05-07 DK DK99921778T patent/DK1083924T3/da active
- 1999-05-07 CZ CZ20004614A patent/CZ294848B6/cs not_active IP Right Cessation
- 1999-05-07 OA OA1200000341A patent/OA11694A/en unknown
- 1999-05-07 PT PT99921778T patent/PT1083924E/pt unknown
- 1999-05-07 CA CA2334872A patent/CA2334872C/en not_active Expired - Fee Related
- 1999-05-07 IL IL14022399A patent/IL140223A0/xx unknown
- 1999-05-07 TR TR2001/00079T patent/TR200100079T2/xx unknown
- 1999-05-07 HU HU0102193A patent/HUP0102193A2/hu unknown
- 1999-05-07 GE GEAP19995661A patent/GEP20033015B/en unknown
- 1999-05-07 PL PL99345212A patent/PL195662B1/pl unknown
- 1999-05-07 KR KR1020007014110A patent/KR20010052800A/ko not_active Ceased
- 1999-05-07 AU AU38899/99A patent/AU758825B2/en not_active Ceased
- 1999-05-07 SK SK1904-2000A patent/SK19042000A3/sk unknown
- 1999-07-05 UA UA2000127165A patent/UA69412C2/uk unknown
2000
- 2000-12-11 IL IL140223A patent/IL140223A/en not_active IP Right Cessation
- 2000-12-12 NO NO20006336A patent/NO20006336L/no not_active Application Discontinuation
- 2000-12-21 BG BG105079A patent/BG64975B1/bg unknown
2003
- 2003-07-03 AU AU2003212050A patent/AU2003212050B2/en not_active Ceased

Also Published As

Publication number	Publication date
OA11694A (en)	2005-01-12
BG64975B1 (bg)	2006-11-30
CN1311687A (zh)	2001-09-05
KR20010052800A (ko)	2001-06-25
DE69918691T2 (de)	2005-07-21
ES2224659T3 (es)	2005-03-01
AU3889999A (en)	1999-12-30
HUP0102193A2 (hu)	2001-10-28
CN1209166C (zh)	2005-07-06
EP1419783A3 (en)	2005-01-12
CZ20004614A3 (en)	2001-06-13
GEP20033015B (en)	2003-07-25
DK1083924T3 (da)	2004-11-22
AU2003212050A1 (en)	2003-08-14
IL140223A (en)	2010-12-30
MXPA00012286A (es)	2002-10-17
WO1999064061A1 (en)	1999-12-16
US7265087B1 (en)	2007-09-04
SK19042000A3 (sk)	2001-11-06
IL140223A0 (en)	2002-02-10
BG105079A (en)	2001-09-28
AU758825B2 (en)	2003-04-03
PL195662B1 (pl)	2007-10-31
AU2003212050B2 (en)	2006-02-16
EP1419783A2 (en)	2004-05-19
BR9911112A (pt)	2001-11-27
EP1083924A1 (en)	2001-03-21
ID28617A (id)	2001-06-21
NZ527473A (en)	2005-02-25
NO20006336L (no)	2001-02-12
PT1083924E (pt)	2004-10-29
ATE270897T1 (de)	2004-07-15
CA2334872A1 (en)	1999-12-16
JP2002517469A (ja)	2002-06-18
AP2001002027A0 (en)	2001-03-31
NZ508823A (en)	2003-10-31
DE69918691D1 (de)	2004-08-19
TR200100079T2 (tr)	2001-06-21
CZ294848B6 (cs)	2005-03-16
EA004538B1 (ru)	2004-06-24
EA200100029A1 (ru)	2001-10-22
CA2334872C (en)	2014-08-19
UA69412C2 (uk)	2004-09-15
EP1083924B1 (en)	2004-07-14
PL345212A1 (en)	2001-12-03

Legal Events

Date	Code	Title	Description
2003-03-03	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
DK1083924T3 (da)	2004-11-22	Glucagon-lignende peptid-1 (GLP-1) forbedrer beta-cellereaktion på glucose i individer med forringet glucosetolerance
DE60002241D1 (de)	2003-05-28	Solarzellenmodul und Solarzellen-Paneel
DE69833862D1 (de)	2006-05-11	Solarzellenmodul
GB9808944D0 (en)	1998-06-24	Electrochemical display and timing mechanism with migrating electrolyte
DE69727581D1 (de)	2004-03-18	RAM-Speicherzelle mit niedriger Leistungsaufnahme
DE69533949D1 (de)	2005-03-03	Sonnenzellenmodul
DE69907918D1 (de)	2003-06-18	Solarzellen-BAUELEMENT
DE69940559D1 (de)	2009-04-23	Elektrochemische zelle mit hohem durchsatz und ansammlungsverfahren
DK0798787T3 (da)	2008-03-25	Fotovoltaisk solarmodul i pladeform
DE60033735D1 (de)	2007-04-19	Sammelschienenstruktur in einer elektrochemischen Zelle
DE69934792D1 (de)	2007-02-22	Antikörper gegen dendritische zellen und menschliche dendritische zellpopulationen und deren verwendungen
FI973262A0 (fi)	1997-08-07	Elektrolyysikennossa käytettävä katodi
DE59810466D1 (de)	2004-01-29	Flüssigelektrolytbatterie mit elektrolytumwälzung
GB0117235D0 (en)	2001-09-05	Improvements in or relating to electrochemical cells
DE69938930D1 (de)	2008-07-31	Antikörper gegen ein antigen auf langerhans zellen in säugetieren und deren verwendungen
ZA200007383B (en)	2001-11-28	Glucagon-like peptide-1 improves β-cell response to glucose in subjects with impaired glucose tolerance.
DE69813017D1 (de)	2003-05-08	Pockelszelle und optischer schalter mit pockelszelle
AU2370195A (en)	1995-11-29	Cell lines obtained by (in vivo) migration and by fusion with autoimmune cells
NO20014011D0 (no)	2001-08-17	Glukosedehydrogenasefusjonsproteiner og deres anvendelse i ekspresjonssystemer
ID21925A (id)	1999-08-12	Peningkatan pada atau yang berhubungan dengan kaca berlapis
AU5683099A (en)	2000-03-14	Blockade of glucose toxicity to the beta cells in the islets of langerhans
AU5236301A (en)	2001-11-26	Improvements in and relating to fuel cell constructions
AU2724899A (en)	1999-08-30	Fuel cell with solid electrolyte and planar structure
GB9818966D0 (en)	1998-10-21	Improvements in or relating to immobilisation of cells
Thompson	1994	Ecunomic aid